Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology..
INTRODUCTION: Coronavirus disease (COVID-19) has spread from Wuhan, China, and become a worldwide pandemic. Most patients display respiratory symptoms but up to 50% report gastrointestinal symptoms. Neopterin is a surrogate marker for viral inflammation, and its production by macrophages is driven by interferon-γ.
METHODS: We measured fecal neopterin in 37 hospitalized COVID-19 patients not requiring intensive care measures and 22 healthy controls.
RESULTS: Fecal neopterin was elevated in stool samples from COVID-19 patients compared with that in samples from healthy controls. Especially, patients reporting gastrointestinal symptoms exhibited increased fecal neopterin values.
DISCUSSION: COVID-19 is associated with an inflammatory immune response in the gastrointestinal tract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Clinical and translational gastroenterology - 12(2021), 1 vom: 12. Jan., Seite e00293 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grabherr, Felix [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
670-65-5 |
|---|
| Anmerkungen: |
Date Completed 25.01.2021 Date Revised 24.10.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.14309/ctg.0000000000000293 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320023273 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320023273 | ||
| 003 | DE-627 | ||
| 005 | 20231225172708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14309/ctg.0000000000000293 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1066.xml |
| 035 | |a (DE-627)NLM320023273 | ||
| 035 | |a (NLM)33438988 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Grabherr, Felix |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2021 | ||
| 500 | |a Date Revised 24.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. | ||
| 520 | |a INTRODUCTION: Coronavirus disease (COVID-19) has spread from Wuhan, China, and become a worldwide pandemic. Most patients display respiratory symptoms but up to 50% report gastrointestinal symptoms. Neopterin is a surrogate marker for viral inflammation, and its production by macrophages is driven by interferon-γ | ||
| 520 | |a METHODS: We measured fecal neopterin in 37 hospitalized COVID-19 patients not requiring intensive care measures and 22 healthy controls | ||
| 520 | |a RESULTS: Fecal neopterin was elevated in stool samples from COVID-19 patients compared with that in samples from healthy controls. Especially, patients reporting gastrointestinal symptoms exhibited increased fecal neopterin values | ||
| 520 | |a DISCUSSION: COVID-19 is associated with an inflammatory immune response in the gastrointestinal tract | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Neopterin |2 NLM | |
| 650 | 7 | |a 670-65-5 |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 700 | 1 | |a Effenberger, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrini, Alisa |e verfasserin |4 aut | |
| 700 | 1 | |a Mayr, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Schwärzler, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Reider, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Enrich, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Fritsche, Gernot |e verfasserin |4 aut | |
| 700 | 1 | |a Wildner, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Bellmann-Weiler, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Günter |e verfasserin |4 aut | |
| 700 | 1 | |a Scholl-Bürgi, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Moschen, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Adolph, Timon E |e verfasserin |4 aut | |
| 700 | 1 | |a Tilg, Herbert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational gastroenterology |d 2010 |g 12(2021), 1 vom: 12. Jan., Seite e00293 |w (DE-627)NLM223422886 |x 2155-384X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g day:12 |g month:01 |g pages:e00293 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14309/ctg.0000000000000293 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 1 |b 12 |c 01 |h e00293 | ||